Fig. 1.

BHTD ameliorated neurological function, reduced infarct volume and improved dyslipidemia. A Relative body weight gain for 14 days. B Survival curve. C Longa score. D mNSS score. (A–D, n = 10) E Representative images of TTC staining. F Quantitative analysis of cerebral infarct areas (n = 4). G Representative images of Nissl staining (scale bar = 50 µm). H Quantification of the Nissl staining (n = 4). I Blood lipid in serum: T-CHO, TG, LDL and HDL (n = 6). All data are shown as mean ± SD. For A–D, ^aP < 0.05, ^aaP < 0.01 and ^aaaP < 0.001, vs the Sham group; ^bP < 0.05, ^bbP < 0.01 and ^bbbP < 0.001, vs the MCAO group; ^cP < 0.05, ^ccP < 0.01 and ^cccP < 0.001, vs the Nimodipine group; ^dP < 0.05, ^ddP < 0.01 and ^dddP < 0.001, compared in three BHTD groups. For E–I, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001